In recent trading session, Boston Scientific Corporation (NYSE:BSX) saw 2,333,725 shares changing hands with its beta currently measuring 0.95. Company’s recent per share price level of $37.11 trading at -$0.61 or -1.62% at recent trade assigns it a market valuation of $53.08 Billion. That current trading price of BSX’s stock is at a discount of -25.63% from its 52-week high price of $46.62 and is indicating a premium of 35.06% from its 52-week low price of $24.1. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 7.96 Million shares which gives us an average trading volume of 8.58 Million if we extend that period to 3-months.
Boston Scientific Corporation (NYSE:BSX) trade information
In the face of being in the red today for losing -1.62%, in the last five days BSX remained trading in the green while hitting it’s week-highest on Friday, Sep 18 when the stock touched $39.99- price level, adding 6.83% to its value on the day. Boston Scientific Corporation’s shares saw a change of -17.6% in year-to-date performance and have moved -6.08% in past 5-day. Boston Scientific Corporation (NYSE:BSX) showed a performance of -4.31% in past 30-days. Number of shares sold short was 14.84 Million shares which calculate 1.73 days to cover the short interests.
Boston Scientific Corporation (BSX) estimates and forecasts
Statistics highlight that Boston Scientific Corporation is scoring comparatively lower than the scores of other players of the relevant industry. The company added +26.07% of value to its shares in past 6 months, showing an annual growth rate of -37.97% while that of industry is 4.9. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -38.5% in the current quarter and calculating -15.2% decline in the next quarter. This year revenue growth is estimated to drop -6.2% from the last financial year’s standing.
22 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.52 Billion for the same. And 22 analysts are in estimates of company making revenue of $2.97 Billion in the next quarter that will end in December 01, 2020. Company posted $2.71 Billion and $2.9 Billion of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -7.1% while estimating it to be 2.2% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 46.4% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -63% while estimates for its earnings growth in next 5 years are of 8.63%
Boston Scientific Corporation (NYSE:BSX)’s Major holders
Insiders are in possession of 0.24% of company’s total shares while institution are holding 95.35% percent of that, with stock having share float percentage of 95.58%. Investors also watch the number of corporate investors in a company very closely, which is 1209 institutions for Boston Scientific Corporation that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at BSX for having 124.15 Million shares of worth $4.36 Billion. And as of June 29, 2020, it was holding 8.68% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 113.12 Million shares on June 29, 2020. The number of shares represents firm’s hold over 7.91% of outstanding shares, having a total worth of $3.97 Billion.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Specialized-Health Care Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 40600525 shares of worth $1.43 Billion or 2.84% of the total outstanding shares. The later fund manager was in possession of 32.26 Million shares on April 29, 2020, making its stake of worth around $1.21 Billion in the company or a holder of 2.25% of company’s stock.